CYTK

CytokineticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$4.28

Analysis reference price unavailable

Analysis 2025-12-10 · RankAlpha Sentiment AI

Most likely

Base case

50%

Probability

Target price

$3.37

Analysis reference price unavailable

Analysis 2025-12-10 · RankAlpha Sentiment AI

B-

Bear case

25%

Probability

Target price

$2.14

Analysis reference price unavailable

Analysis 2025-12-10 · RankAlpha Sentiment AI

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2025-12-10

AI commentary

Market commentary is mixed but tilted toward cautious optimism after recent filings: the 10-Q reiterated cash/runway items and R&D progress while an 8-K noted regulatory interactions that could be binary for value [#10-Q-2025-11-05][#8-K-2025-10-22]. Investor focus centers on upcoming clinical/regulatory milestones and any partnership payments; headlines to watch are trial readouts and FDA decisions [#PIPELINE-2025].

RankAlpha Sentiment AI - 2025-12-10

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventRegulatory interactions / FDA meeting(s)High impact

Company disclosed recent FDA interactions in an 8-K that could clarify regulatory pathway for lead programs; outcome would materially re-rate the stock [#8-K-2025-10-22].

-eventQuarterly operating results / cash-runway update (10-Q)High impact

Q3 2025 filing/earnings provided updated cash runway and R&D guidance; subsequent quarter filings/updates could change financing outlook [#10-Q-2025-11-05].

-catalystClinical readouts for pipeline candidatesHigh impact

Multiple pipeline programs (cardiac/neuromuscular muscle modulators) have pending development milestones; positive/negative readouts would drive significant revaluation [#PIPELINE-2025].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-12-10 • Updated nightlySource: Internal modelMethodology